Home News News National Institute on Aging invests an additional $7.3 million into NU-9 December 17, 2024 By Ver_ak@va This article is sourced from an external publication. Read the original → ← PreviousAkava Therapeutics, Inc. Announces FDA Clearance of Investigational New Drug Application for the Treatment of Amyotrophic Lateral SclerosisNext →Akava Therapeutics, Inc. congratulates SAB Chair Dr. Hande Ozdinler, Founder Dr. Richard B. Silverman, and Dr. William Klein on their recent grant of $7.3 million from the National Institute on Aging to investigate AKV9 in neurodegenerative diseases
